Colin John Meyer is Chief Innovation Officer at REATA PHARMACEUTICALS INC (RETA). They have made 10 open-market trades across 1 company since 2016, most recently 2023-09-26.
CIK 0001662392
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $338K since 2016, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RETA | 82,229 | $14.2M |
Shares reported on the most recent Form 4, priced at the 2023-08-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RETA | SELL | 2023-08-15 | 2023-08-17 | $169.00 | $926K | -0.1% | +1.8% | N/A |
| RETA | SELL | 2023-05-15 | 2023-05-17 | $84.56 | $1.1M | +10.2% | +14.7% | +107.8% |
| RETA | SELL | 2023-03-07 | 2023-03-08 | $84.57 | $105K | +9.4% | +15.0% | +15.0% |
| RETA | SELL | 2023-03-02 | 2023-03-06 | $86.72 | $16.3M | +2.8% | +6.0% | +5.3% |
| RETA | SELL | 2021-06-14 | 2021-06-16 | $142.49 | $16.4M | +6.7% | -9.9% | -24.9% |
| RETA | SELL | 2020-11-16 | 2020-11-18 | $169.79 | $8.0M | -8.9% | -27.0% | -25.4% |
| RETA | SELL | 2020-11-09 | 2020-11-10 | $175.00 | $4.4M | -11.5% | -32.6% | -38.3% |
| RETA | BUY | 2016-08-16 | 2016-08-17 | $16.26 | $114K | +18.5% | +84.4% | +111.8% |
| RETA | BUY | 2016-08-16 | 2016-08-17 | $16.26 | $114K | +18.5% | +84.4% | +111.8% |
| RETA | BUY | 2016-06-01 | 2016-06-02 | $11.00 | $110K | +37.2% | +12.0% | +20.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.